Jump to content

Ariel Beresniak

From Wikipedia, the free encyclopedia

Ariel Beresniak
Born (1961-12-03) 3 December 1961 (age 63)
Paris, France
NationalitySwiss
Known forDeveloping innovative approaches in Health technology assessment
Scientific career
FieldsPublic Health, Health Economics
InstitutionsData Mining International Plekhanov Russian Economic University

Ariel Beresniak (born 3 December 1961) is a Swiss specialist in Public Health and Health Economics, author of reference books and scientific articles in modeling and decision-making analyses.

Biography

[edit]

Beresniak is a physician specialized in public health from the Faculty of Medicine at University of Marseille, France .[1] He also obtained a master's degree in Economics and a PhD in applied mathematics in Economics at the Claude-Bernard University (France), and an Accreditation to Supervise Research (Habilitation a Diriger des Recherches).[2] Beresniak was Chief Medical Officer of Epidemic Surveillance in Gabon in 1989 before contributing to implement medico-economic methodologies in the pharmaceutical industry for assessing the value of innovative treatments. He was Head of Health Economics for Glaxo-Wellcome (1993-1999) and Global Head of Pharmacoeconomics for Serono International (1999-2004).[3] Since 2005, Beresniak is CEO of Data Mining International. He has been short-term consultant for the World Health Organization and the European commission in the fields of Public health and Health Economics.[4]

Scientific contribution

[edit]

Beresniak is author of the reference book "Health Economics" published in French and Portuguese.[5][6] He publishes two dictionaries: one dictionary of Health Economics published in French and Spanish, and one dictionary of terms used in health industries published in French.[7][8] Beresniak is also coauthor of "Understanding Pharmacoeconomics" published in French and "Pharmacoeconomics" published in Japanese.[9][10] Beresniak is known to have led the ECHOUTCOME project, a European Commission funded research, establishing that the QALY indicator (Quality Adjusted Life Years) is not scientifically validated to be used in Decision making and could lead to divergent results with the same dataset.[11] These findings have generated an international controversy because the QALY indicator is still currently promoted as reference case by some national health technology assessment agencies such as the NICE (National Institute for Health and Care Excellence) in the UK.[12][13] Beresniak was also project leader of the FLURESP project, a European Commission funded research, with the objective to compare cost-effectiveness of 18 public health interventions against human pandemic influenza. Beresniak confirmed the value of universal influenza vaccination of the entire population, which is a strategy appearing more "cost-effective" compared to vaccination limited to "at-risk groups" as still widely recommended by health authorities. Beresniak also found that the most effective measures against influenza epidemic mortality are the development of more intensive care units equipped with ECMO extracorporeal oxygenation platforms for managing acute respiratory distress syndrome (ARDS).[14]

References

[edit]
  1. ^ "SFES - Société Française en Economie de la Santé". www.sfes.info. Archived from the original on 16 September 2013.
  2. ^ "Home".
  3. ^ A Beresniak, F Taboulet, Comprendre la Pharmacoéconomie, John Libbey Eurotext, 1996:125 p ISBN 978-2-7420-0144-6
  4. ^ Beresniak, Ariel; Napoli, Christian; Oxford, John; Daruich, Alejandra; Niddam, Laurent; Duru, Gérard; Tozzi, Alberto E.; Atti, Marta Ciofi Degli; Dupont, Danielle; Rizzo, Caterina; Bremond-Gignac, Dominique (15 May 2023). "The FLURESP European commission project: cost-effectiveness assessment of ten public health measures against influenza in Italy: is there an interest in COVID-19 pandemic?". Cost Effectiveness and Resource Allocation: C/E. 21 (1): 30. doi:10.1186/s12962-023-00432-0. ISSN 1478-7547. PMC 10184089. PMID 37189126.
  5. ^ A Beresniak, G Duru, Economie de la santé, 6ième édition, Coll. des abrégés de médecine - MASSON 2007:180 p ISBN 978-2-294-08850-6
  6. ^ A. Beresniak, G. Duru, Economia da Saude, Climepsi editors 1999:162 p ISBN 978-972-8449-14-8
  7. ^ JP Auray, A Beresniak, JP Claveranne, G Duru, Dictionnaire commenté d’Economie de la santé, Coll. des abrégés de médecine -Edition MASSON 1996: 289 p ISBN 978-2-225-85284-8
  8. ^ JP Auray, A Beresniak, JP Claveranne, G Duru, Diccionario comentado de Economia de la salud, Editorial MASSON-Barcelona 1998: 351p ISBN 978-84-458-0597-8
  9. ^ A Beresniak, F Taboulet, Comprendre la Pharmacoéconomie, John Libbey Eurotext, 1996:125 p ISBN 978-2-7420-0144-6
  10. ^ K Tsutani, A Beresniak, 薬剤経済学の活用 医薬品の経済的エビデンスをつくる・つかう, Elsevier Japan, 2008:144p ISBN 978-4-86034-564-8
  11. ^ Orpha News, Interview with Ariel Beresniak, 16 March 2006, http://www.orpha.net/actor/EuropaNews/2006/060316.html
  12. ^ BBC News, J Dreaper, Researchers claim NHS drug decisions are flawed, 24 Jan 2013, https://www.bbc.co.uk/news/health-21170445
  13. ^ Nature Medicine, D Holmes, Report triggers quibbles over QALYs, a staple of health metrics, Vol 19, Numb 3, March 2013
  14. ^ Ariel Beresniak, Caterina Rizzo, John Oxford et Paweł Goryński, « Cost-effectiveness of public health interventions against human influenza pandemics in France: a methodological contribution from the FLURESP European Commission project », European Journal of Public Health, 5 mai 2019, ckz074 (ISSN 1101-1262 et 1464-360X, DOI 10.1093/eurpub/ckz074
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ariel_Beresniak&oldid=1240134635"